The Lancet · Online First· Brian M Slomovitz, Jianqing Zhu, Rutie Yin, Floor Backes, Mariusz Bidziński, Lucy Gilbert, Lyndsay J Willmott, Kosei Hasegawa, Jae-Weon Kim, Judith R Kroep, Ignacio Romero, Murat Gultekin, Peng-Hui Wang, Sally Baron-Hay, Jaroslav Klát, Ora Rosengarten, Maggie Polignano, Marcela Berrios, Karen Cadoo, Heini Lassus, Beata Maćkowiak-Matejczyk, Domenica Lorusso, Anna K L Reyners, Elizabeth R Burton, Vicky Makker, Lili Yao, Robin Meng, Robert Orlowski, Sandro Pignata·· 2 小时前精选AI 评分65
KEYNOTE-C93/GOG-3064/ENGOT-en15期中分析：一线帕博利珠单抗改善错配修复缺陷晚期或复发性子宫内膜癌无进展生存期
[Articles] First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
AI 导读
KEYNOTE-C93/GOG-3064/ENGOT-en15显示，一线帕博利珠单抗（pembrolizumab）较卡铂联合紫杉醇改善错配修复缺陷晚期或复发性子宫内膜癌患者的无进展生存期，差异具有统计学显著性和临床意义。
推荐理由
该试验以化疗而非当前免疫联合化疗标准治疗为对照，因此其结果不能直接回答帕博利珠单抗单药与现行标准治疗的比较问题。
来源：The Lancet · Online First · thelancet.com